These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 22496204)

  • 1. Mutations in the Ras-Raf Axis underlie the prognostic value of CD133 in colorectal cancer.
    Kemper K; Versloot M; Cameron K; Colak S; de Sousa e Melo F; de Jong JH; Bleackley J; Vermeulen L; Versteeg R; Koster J; Medema JP
    Clin Cancer Res; 2012 Jun; 18(11):3132-41. PubMed ID: 22496204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/β-catenin signaling.
    Moon BS; Jeong WJ; Park J; Kim TI; Min do S; Choi KY
    J Natl Cancer Inst; 2014 Feb; 106(2):djt373. PubMed ID: 24491301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of CD133 caused by mutant K-Ras and B-Raf--letter.
    Fornaro L; Crea F; Masi G; Di Paolo A; Vivaldi C; Danesi R; Falcone A
    Clin Cancer Res; 2012 Aug; 18(16):4473; author reply 4474. PubMed ID: 22811585
    [No Abstract]   [Full Text] [Related]  

  • 4. Relationships among
    Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
    World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential expression of CD133 based on microsatellite instability status in human colorectal cancer.
    Park JJ; Kwon JH; Oh SH; Choi J; Moon CM; Ahn JB; Hong SP; Cheon JH; Kim TI; Kim H; Kim WH
    Mol Carcinog; 2014 Feb; 53 Suppl 1():E1-10. PubMed ID: 23065858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptome analysis of CD133-positive stem cells and prognostic value of survivin in colorectal cancer.
    Kim ST; Sohn I; DO IG; Jang J; Kim SH; Jung IH; Park JO; Park YS; Talasaz A; Lee J; Kim HC
    Cancer Genomics Proteomics; 2014; 11(5):259-66. PubMed ID: 25331798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the K-ras/B-raf/Erk signal cascade, p53 and CMAP as markers for tumor progression in colorectal cancer patients.
    Georgieva M; Krasteva M; Angelova E; Ralchev K; Dimitrov V; Bozhimirov S; Georgieva E; Berger MR
    Oncol Rep; 2008 Jul; 20(1):3-11. PubMed ID: 18575712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients.
    Reggiani Bonetti L; Migaldi M; Caredda E; Boninsegna A; Ponz De Leon M; Di Gregorio C; Barresi V; Scannone D; Danese S; Cittadini A; Sgambato A
    Scand J Gastroenterol; 2012 Oct; 47(10):1211-7. PubMed ID: 22856425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data.
    Bahnassy AA; Fawzy M; El-Wakil M; Zekri AR; Abdel-Sayed A; Sheta M
    Transl Res; 2015 Mar; 165(3):396-406. PubMed ID: 25168019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases.
    Jing F; Kim HJ; Kim CH; Kim YJ; Lee JH; Kim HR
    Int J Oncol; 2015 Apr; 46(4):1582-8. PubMed ID: 25625240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice.
    Wang D; Fu L; Sun H; Guo L; DuBois RN
    Gastroenterology; 2015 Dec; 149(7):1884-1895.e4. PubMed ID: 26261008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
    Le H; Zeng F; Xu L; Liu X; Huang Y
    Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A gene signature distinguishing CD133hi from CD133- colorectal cancer cells: essential role for EGR1 and downstream factors.
    Ernst A; Aigner M; Nakata S; Engel F; Schlotter M; Kloor M; Brand K; Schmitt S; Steinert G; Rahbari N; Koch M; Radlwimmer B; Weitz J; Lichter P
    Pathology; 2011 Apr; 43(3):220-7. PubMed ID: 21436631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell lines HCT-116.
    Dittfeld C; Dietrich A; Peickert S; Hering S; Baumann M; Grade M; Ried T; Kunz-Schughart LA
    Radiother Oncol; 2009 Sep; 92(3):353-61. PubMed ID: 19699546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer.
    Wang C; Xie J; Guo J; Manning HC; Gore JC; Guo N
    Oncol Rep; 2012 Oct; 28(4):1301-8. PubMed ID: 22895640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
    Dahlrot RH
    Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha.
    Soeda A; Park M; Lee D; Mintz A; Androutsellis-Theotokis A; McKay RD; Engh J; Iwama T; Kunisada T; Kassam AB; Pollack IF; Park DM
    Oncogene; 2009 Nov; 28(45):3949-59. PubMed ID: 19718046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation.
    Ikenoue T; Hikiba Y; Kanai F; Aragaki J; Tanaka Y; Imamura J; Imamura T; Ohta M; Ijichi H; Tateishi K; Kawakami T; Matsumura M; Kawabe T; Omata M
    Cancer Res; 2004 May; 64(10):3428-35. PubMed ID: 15150094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A gene marker panel covering the Wnt and the Ras-Raf-MEK-MAPK signalling pathways allows to detect gene mutations in 80% of early (UICC I) colon cancer stages in humans.
    Scholtka B; Schneider M; Melcher R; Katzenberger T; Friedrich D; Berghof-Jäger K; Scheppach W; Steinberg P
    Cancer Epidemiol; 2009 Aug; 33(2):123-9. PubMed ID: 19679059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
    Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
    Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.